Kanion Pharmaceutical To Set Up Production Facility In Zhongshan
This article was originally published in PharmAsia News
Executive Summary
Kanion Pharmaceutical Co. Ltd. has signed an agreement with Zhongshan city in Guangdong province to set up an anti-tumor drug production base and R&D center. It has committed an initial investment of 280 million yuan. The annual production value is projected to reach 2 billion yuan when the facility is in full operation. The Modern Chinese Medicine Park of South China promises to provide support in terms of land, location, R&D, tax relief, registration and other industry services. Kanion is a top-50 TCM enterprise and its key product, Guizhi Fuling soft gel capsule, has received approval for a Phase II clinical trial in the U.S. (Click here for more - Chinese Language)